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Abstract
Objective. To evaluate the potential of autologous dendritic cells (DC) pulsed with HPV16 and HPV18 E7 oncoprotein in restoring
tumor-specific cytotoxicity in populations of tumor infiltrating lymphocytes (TIL) for adoptive immunotherapy of cervical cancer patients.
Methods. Full-length E7-pulsed DC-stimulated CD8 T cells derived from peripheral blood (PBL) and from tumor tissues (TIL) were tested
and compared for their ability to induce a HLA class-I-restricted cytotoxic T lymphocyte (CTL) response against autologous tumor cells. In
addition, in order to correlate cytotoxic activity by CTL with a particular lymphoid subset, analysis of surface antigens and intracellular CD3 
chain and two-color flow cytometric analysis of intracellular cytokine expression (IFN- vs IL-4) at the single cell level were performed.
Results. DC stimulation induced powerful cytotoxicity against autologous tumor target cells by TIL-derived CD8 T cells from all three
cervical cancer patients, while autologous Epstein–Barr virus-transformed lymphoblastoid cell lines were not lysed. Killing of autologous
tumor cells was higher by CD8 T cells from TIL compared to PBL (P  0.01) and was more strongly inhibited by anti-HLA class I MAb
(P  0.05). Phenotypically, all CTL populations were CD3/CD8, with higher levels of CD56 expression by TIL-derived CTL. Finally,
although a marked Type 1 cytokine bias (i.e., IFN-high/IL-4low) was observable in both PBL- and TIL-derived DC-stimulated CD8 T cell
populations, TIL-derived CD8 T cells showed a higher percentage of IFN--positive cells compared to PBL.
Conclusions. Full-length E7-pulsed DC can consistently restore strong CD8 CTL responses against autologous HPV16- and HPV18-
infected cervical cancer cells. DC-stimulated TIL may represent a superior source of tumor-specific CTL compared to PBL for adoptive T
cell immunotherapy of patients harboring metastatic or recurrent cervical cancer refractory to standard treatment modalities.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Management of disseminated carcinoma of the cervix no
longer amenable to control with surgery or radiation therapy
has not improved significantly with the progress of modern
chemotherapy, with a 1-year survival rate of 10% [1]. Novel
therapeutic strategies effective in the treatment of metastatic
and/or recurrent disease are still desperately needed. Human
papillomavirus (HPV)1 infection from high-risk genotypes
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(i.e., HPV16 and HPV18) represents the most important risk
factor for developing cervical cancer and more than 90% of
cervical cancers contain integrated viral genes encoding two
specific oncoproteins (E6 and E7)[2,3]. Although the inter-
actions between the host immune system and HPV-infected
cells are still not completely understood, cell-mediated im-
munity seems to play an important role in the control of
HPV-associated malignancy. In support of this view, sub-
stantial evidence has shown increased incidence of associ-
ated genital cancer and a more rapid progression of HPV-
infected tumors in immunosuppressed patients, while only a
minority of genital HPV infections result in the develop-
ment of cancer in otherwise healthy individuals [4–6].
Infiltrating CD4 (helper) and CD8 (cytotoxic/suppressor)
T cells and NK cells have been observed in spontaneously
regressing HPV-associated warts [7,8], and the degree of
lymphoid cell infiltration of the neoplastic cervix [9] and the
ability of such reactive cells to secrete the immunostimula-
tory and antiviral cytokine IFN- [10] have been reported to
be independent factors for disease-free survival in cervical
cancer patients. Better prognosis in early-stage HPV-posi-
tive cervical carcinoma than HPV-negative disease has been
previously reported [11]. Studies in animals have demon-
strated that immunized animals are protected from papillo-
mavirus infections and from transplanted tumor cells ex-
pressing HPV E6/E7 viral proteins [12–14]. Finally, the
detection of in vivo-primed HPV-specific T cells as well as
the in vitro generation of HPV-specific cytotoxic T lympho-
cytes (CTL) has recently been reported in cervical cancer
patients [15–18].
Dendritic cells (DC) are the most potent professional
antigen presenting cells (pAPC) for activation of T and B
cell immune responses [19] and recently the combination of
GM-CSF and IL-4 has been shown to generate large num-
bers of DC for the manipulation of human T cell responses
[20,21]. In the last few years, human phase I trials have been
initiated using peptide/protein pulsed DC, and promising
results have been reported for several human tumors, with-
out significant side effects from the vaccinations [22–26].
One of the most important components of successful
tumor-specific adoptive immunotherapy is the activation
and expansion of large numbers of tumor-specific T lym-
phocytes. In support of this view, tumor infiltrating lym-
phocytes (TIL) have been shown to be a reliable source of
tumor-specific CTL precursors for effective adoptive immu-
notherapy [27,28]. However, in several studies, lympho-
cytes derived from TIL have been shown to be defective in
several immunologic functions, including (1) the ability to
proliferate in the presence of mitogens, phorbol esters, or
low doses of IL-2, (2) cytotoxic activity against autologous
or allogeneic tumor cells, (3) effector activity in assays of
natural killing, and (4) expression of cytoplasmic CD3 
chain, which is essential for T cell receptor (TcR) signaling
[reviewed in 29,30]. Although the mechanisms responsible
for these impaired immune responses are yet not completely
understood, in some cases, poor immune responses by re-
cently explanted T lymphocytes could be normalized upon
in vitro culture with recombinant IL-2 [31] or by T cell
stimulation with anti-CD3 and anti-CD28 antibodies [32]. It
is therefore possible that when properly reactivated by ma-
ture tumor antigen-pulsed DC, which are endowed with
high expression of HLA class I and II antigens and costimu-
latory molecules [33], lymphocytes derived from TIL may
be a superior source of tumor-specific CTL for adoptive T
cell immunotherapy for cervical cancer.
In this study we have evaluated and compared the phe-
notype and function of HPV16 and HPV18 E7-pulsed au-
tologous DC-stimulated CD8 T lymphocytes derived from
PBL and TIL of cervical cancer patients. Here we show for
the first time that full-length E7-pulsed fully mature DC
have the potential to consistently reverse the anergic state of
TIL populations derived from cervical cancer patients and
that TIL constitute a superior source of tumor-specific
CD8 CTL compared to PBL for potential use in adoptive
immunotherapy of cervical cancer patients unresponsive to
standard salvage treatment modalities.
Materials and methods
Patients
Three patients who had undergone radical hysterectomy
for invasive cervical cancer provided tumor tissue and pe-
ripheral blood lymphocytes. Specimens were obtained at the
time of surgery through the Division of Gynecologic On-
cology and the Pathology Department at the University of
Arkansas for Medical Sciences (UAMS), Little Rock, Ar-
kansas, under approval of the Institutional Review Board.
HPV typing was performed on fresh tissue biopsy and on
the derived fresh cultures by PCR using sequence-specific
primers for HPV -16, -18, -31, -33, -52b, and -58 [34].
Patients 1 and 2 had stage IB2 squamous cell carcinomas
positive for HPV 16 and were ages 35 and 37, while patient
3 had stage IB2 adenocarcinoma positive for HPV 18 and
was age 31.
Tumor cell lines
Fresh tumor cells were obtained from multiple punch
biopsies from all patients. Biopsies were divided into two
parts, for histopathologic evaluation and for in vitro studies.
Fresh tumor cell lines were maintained in serum-free kera-
tinocyte medium (KSFM, Invitrogen, Grand Island, NY),
supplemented with 5 ng/ml of epidermal growth factor and
35 to 50 g/ml of bovine pituitary extract at 37°C, 5% CO2.
Briefly, single cell suspensions were obtained by processing
solid tumor samples under sterile conditions at room tem-
HLA, human leukocyte antigens; IFN-, interferon-gamma; IL-4, interleu-
kin-4.
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perature. Viable tumor tissue was mechanically minced in
RPMI 1640 to portions no larger than 1–3 mm3 and washed
twice with RPMI 1640. The portions of minced tumor were
then placed into 250-ml trypsinizing flasks containing 30 ml
of enzyme solution [0.14% Collagenase Type I (Sigma, St.
Louis, MO) and 0.01% DNase (Sigma, 2000 KU/mg)] in
RPMI 1640 and incubated on a magnetic stirring apparatus
overnight at 4°C. Enzymatically dissociated tumor was then
filtered through 150-m nylon mesh to generate a single
cell suspension. The resultant cell suspension was then
washed twice in RPMI 1640 plus 10% autologous plasma.
All experiments were performed with fresh or cryopre-
served tumor cultures which had at least 90% viability and
contained 99% tumor cells.
Collection and isolation of peripheral blood lymphocytes
(PBL) from cervical cancer patients
Peripheral blood was collected in heparinized tubes and
processed as previously described [34], to separate the
mononuclear leukocytes from red blood cells by Ficoll–
Hypaque density gradient centrifugation. The leukocytes
were subsequently harvested, washed twice in phosphate-
buffered saline (PBS, pH 7.2), and either seeded in six-well
plates in AIM-V medium (Invitrogen) for DC generation as
described below or resuspended in RPMI 1640 plus 5%
human AB serum (Gemini BioProducts, Calabasas, CA)
before staining with monoclonal antibodies (MAb).
Isolation of TIL
Specimens were obtained at the time of diagnosis or
surgery. Briefly, tumor cells and TIL single cell suspensions
were obtained by processing solid tumor samples under
sterile conditions as described above. Cell suspensions con-
taining tumor cells and TIL were then washed twice in
RPMI 1640 plus 10% autologous plasma, placed on discon-
tinuous Ficoll–Hypaque (75/100%) density gradients, and
centrifuged again to separate and harvest TIL and tumor
cells as previously described [35]. Enriched TIL prepara-
tions were then washed twice in RPMI 1640 plus 10%
autologous plasma and either immediately activated with
PMA and ionomycin for intracellular cytokine studies or
incubated overnight at 37°C in tissue culture flasks before
collecting the TIL from the nonadherent population.
DC cultures and generation of HPV E7-specific T cells
The derivation of DC from the patients’ PBMC, and their
subsequent use for generation of HPV E7-specific T cells,
was carried out essentially as described [34]. E7-specific
CD8 T cells were derived from cervical cancer patients
from lymphocytes obtained from PBL and tumor tissue
(TIL). Briefly, DC were generated from plastic-adherent
PBMC by culture in AIM-V medium plus 800 U/ml of
GM-CSF (Immunex, Seattle, WA) and 500 U/ml of IL-4 (R
& D Systems, Minneapolis, MN). Cultures were fed by
half-changes of AIM-V plus GM-CSF and IL-4 every 2
days. Final maturation of monocyte-derived DC was in-
duced by exposure during the last 48 h of culture (i.e., days
6 to 8) to TNF- (1000 U/ml) IL-1 (500 U/ml) (R & D
Systems), and PGE2a (0.5 M/ml) (Sigma). The DC purity
(i.e., cells strongly expressing HLA-DR, CD86, CD83,
CD80, CD40, and CD14) ranged from 62 to 90% of the
total cell population, as previously characterized by our
laboratory [33]. After final maturation, DC were harvested
for pulsing with HPV16 or 18 E7 oncoproteins generated
using previously characterized plasmids encoding glutathi-
one S–transferase (GST) E7 fusion proteins [34]. The cat-
ionic lipid DOTAP (Boehringer Mannheim, Indianapolis,
IN) was used to deliver the HPV16 or 18 E7 proteins into
cells as described [34]. HPV E7-specific CTL were gener-
ated by culturing responder PBMC and TIL (10–20  106
cells/well in 6-well culture plates) (Costar, Cambridge, MA)
in AIM-V with E7-pulsed autologous DC (ratios from 20:1
to 30:1 responder PBMC/TIL: DC). The cultures were sup-
plemented with recombinant human IL-2 (10 U/ml of Al-
desleukin, Chiron Therapeutics, Emeryville, CA) and re-
stimulated once with E7-pulsed DC after 10–14 days. At
day 21–28, CD8 T cells were separated from the bulk
cultures by positive selection with CD8 Dynabeads (Dynal
Inc., Lake Success, NY) and further expanded in number for
5–7 days using autologous or allogeneic irradiated PBL
(5000 cGy) (1  106 cells/well) and anti-CD3 MAb (0.2
g/ml) plus 5% autologous plasma and 100 U/ml of IL-2 in
24-well plates (Costar), before being assayed for phenotype
characteristic and CTL activity.
Flow cytometric analysis of surface antigens, intracellular
CD3  chain, and cytokines by cervical tumor-specific
CTL from PBL and TIL
Flow cytometric analysis of superficial antigens and in-
tracellular cytokine expression was conducted essentially as
previously described [36]. Briefly, flow cytometry for su-
perficial antigen expression analysis was performed using
directly conjugated MAbs against the following markers:
CD3, pan T cells; CD4, T helper/inducer; CD8, T cytotoxic/
suppressor; CD19, B cells; CD56, NK/K cells; CD25, the
IL-2 receptor; anti-HLA-DR; and anti-TcR / (all from
Becton–Dickinson, San Jose, CA). Control isotype-matched
FITC- or PE-conjugated MAb were also obtained from
Becton–Dickinson. For evaluation of the level of CD3
chain in CD8 T cells, PBL and TIL before and after in
vitro stimulation with HPV16 or HPV18 E7-pulsed DC
were harvested, stained with anti-CD8-FITC (Becton–Dick-
inson), washed, and fixed with 2% paraformaldehyde in
PBS for 20 min at room temperature. Cells were then
washed and permeabilized by incubation in PBS plus 1%
BSA (A-3059, Sigma) and 0.5% saponin (S-7900, Sigma)
for 10 min at room temperature. Experimental and control
cells were stained with anti-TcR-PE (2H2D9-IgG1k) or
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isotype control (Coulter, Marseille, France). After staining,
cells were washed twice with PBS plus 1% BSA and 0.5%
saponin, once with PBS plus 0.5% BSA, and fixed a second
time with 2% paraformaldehyde in PBS. All analyses were
conducted with a FACScan, utilizing Cell Quest software
(Becton–Dickinson).
For intracellular cytokine staining for IFN- and IL-4
expression, CD8 T cells obtained from PBL and TIL at
the beginning of culture were activated with 50 ng/ml
PMA and 500 ng/ml of ionomycin for 6 h; 10 g/ml of
Brefeldin A was added for the final 3 h of incubation.
Controls (nonactivated cultures) were incubated in the
presence of Brefeldin A only. Cells were superficially
stained with anti-CD8-FITC or anti-CD8-PE MAb and
then washed and permeabilized by incubation in PBS
plus 1% BSA and 0.5% saponin for 10 min at room
temperature. Activated and control cells were stained
with FITC-anti-IFN- and/or PE-anti-IL-4 and isotype-
matched controls (FITC-anti-Ig2a and PE-anti-Ig1)
(Becton–Dickinson). Purified DC-stimulated CD8 T
cell populations (i.e., day 21–28 of culture) were also
analyzed by two-color flow cytometry for simultaneous
expression of IFN- and IL-4 at the single cell level.
After staining, cells were washed twice with PBS plus
1% BSA and 0.5% saponin, once with PBS plus 0.5%
BSA, and fixed a second time with 2% paraformaldehyde
in PBS.
Cytotoxic activity
A 6-h chromium (51Cr) release assay was performed as
previously described [34] to measure the cytotoxic reactiv-
ity of DC-E7-stimulated T lymphocytes. The EBV-trans-
formed lymphoblastoid B cell line (LCL) derived from the
same cancer patient that provided the HPV naturally in-
fected primary tumor cell targets was established by cocul-
ture of PBMC with EBV-containing supernatant from the
B95.8 cell line in the presence of 1 g/ml of cyclosporin A
(Sandoz, Camberley, UK) and was maintained in RPMI
1640 supplemented with 10% human AB serum. To deter-
mine the molecular basis of target cell lysis, 51Cr-labeled
tumor targets were preincubated with MAbs specific for
monomorphic HLA class I (W6/32, 50 g/ml) or isotype
control MAb. The effector cells and 51Cr-labeled targets
were then incubated in a final volume of 200 l/microwell
at 37°C with 6% CO2.
Statistical analysis
Data were analyzed using the Student’s t test. All
data were expressed as mean percentages of positive
cells  standard deviation (SD). In all tests, the differ-
ence was considered significant when P values were less
than 0.05.
Results
Phenotypic analysis of lymphocytes from peripheral blood
and tumor tissue
Flow cytometric analysis was used to characterize the
phenotype of the populations of lymphocytes obtained from
PBL and TIL before and after the in vitro stimulation with
autologous HPV16 or HPV18 E7-loaded DC. The propor-
tions of CD3, CD8, and CD4 T cells in PBL and TIL
from the three cervical cancer patients evaluated in this
study before DC activation are described in Table 1. CD3
T cells were the major lymphocyte population in each tis-
sue, with the percentage of CD4 T cells greater than the
percentage of CD8 T cells in PBL (P 0.01) (Table 1). In
contrast, in all three patients, TIL contained a significantly
higher percentage of CD8 T cells (Table 1). The PBL had
a CD4 to CD8 ratio of 2:1, while TIL showed a ratio of
0.8:1 (Table 1). Starting lymphocyte populations were also
different in the percentage of CD56- and CD19-positive
lymphocytes, with PBL containing more CD56 and
CD19 cells than TIL (P  0.05 and P  0.01 for CD56
and CD19, respectively). The expression of CD56 on T
lymphocytes was further analyzed by two-color immuno-
fluorescence. By this technique, the CD8 T cells were
compared for coexpression of CD56. PBL contained more
CD8/CD56 T cells than TIL (Table 1, P  0.05).
After 21–28 days of culture of HPV16 or HPV18 E7-
pulsed DC-stimulated PBL and TIL, the striking majority of
cells were found to be TcR-/CD3 T cells (93–98%).
PBL contained more CD4 T cells (range, 58–89%) than
CD8 T cells. In contrast, in the TIL populations derived
from all three patients, CD8 T cells (range, 55–78%) were
predominant over CD4 T cells. Enriched populations of
CD8 T cells were isolated at this time and analyzed for
expression of CD56 after a further 2 or more weeks of
culture. A variable proportion of CD8/CD56 antigen-posi-
tive cells was detected in all CD8 T cells derived from
PBL and TIL. However, as representatively shown for pa-
Table 1
Subpopulations of mononuclear cells in PBL and TIL from cervical
cancer patients
Specific MAb % Phenotype
Patient 1 Patient 2 Patient 3
PBL TIL PBL TIL PBL TIL
CD3 74 42 69 49 66 39
CD4 50 20 46 21 44 18
CD8 24 22 22 25 23 22
CD19 13 3 15 3 12 2
CD56 9 3 17 2 9 3
CD8/CD56 5 2 8 2 6 1
CD4/CD8 RATIO 2.1 0.9 2.1 0.8 1.9 0.8
Values are percentages of PBL and TIL that are positive for specific
markers used in the cell staining before stimulation with E7-pulsed autol-
ogous dendritic cells.
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tient 1 (Fig. 1), HPV16 or HPV18 E7-DC-stimulated TIL
consistently expressed a higher percentage of CD8/
CD56 T cells than PBL (P  0.01). Further analysis
revealed the populations of CD8 T cells from PBL and
TIL to be CD25, HLA-DR, and CD16 (data not
shown).
Expression of intracellular TcR  chain in cervical tumor
antigen-stimulated T cells
To evaluate whether the expression levels of TcR  chain
vary significantly in PBL and TIL collected from cervical
cancer patients before and/or after DC stimulation, we again
took advantage of flow cytometry. As shown in Table 2, the
mean fluorescence intensity (MFI) of TcR  chain expres-
sion was significantly higher in CD8 T cells derived from
PBL than in those derived from TIL (P  0.05) in all three
patients. However, after DC stimulation and expansion no
significant differences were found in TcR  chain expres-
sion among CD8 T cells derived from PBL compared to
TIL (data not shown).
Tumor-specific cytotoxic responses in CD8 T cells
derived from PBL and TIL
Cytotoxicity assays on HPV16 or HPV18 E7-loaded
DC-stimulated PBL and TIL were conducted after a mini-
mum of 2 weeks following separation of pure populations of
Fig. 1. Two-color flow cytometric analysis of CD56 expression by CD8 T cells in PBL and TIL from a representative patient before and after in vitro
stimulation with full-length HPV16 E7-loaded DC. Numbers in the upper right quadrant represent the percentages of CD8 CD56 T cells. (Left) PBL and
TIL before DC stimulation. (Right) PBL and TIL after DC stimulation.
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CD8 T cells. The results in Fig. 2 represent the mean of
not less than three assays for each patient. Cytototoxic
activity of DC-stimulated CD8 T cells ranged from 28 to
46%, mean 38% (PBL), and from 38 to 63%, mean 53%
(TIL), for patient 1; from 18 to 36%, mean 28% (PBL), and
from 33 to 58%, mean 49% (TIL), for patient 2; and from 26
to 40%, mean 33% (PBL), and from 54 to 73%, mean 63%
(TIL), for patient 3. Blocking studies indicated that in all
cases tumor-specific lysis by CD8 T cells was inhibited by
MAb specific for HLA class I, the range of inhibition being
from 18 to 57% (PBL) and from 38 to 84% (TIL) for the
three patients. In all cases low or negligible cytotoxicity was
observed against autologous EBV-transformed LCL and
against natural killer-sensitive K562 cells (Fig. 2). In con-
trast with the tumor-specific cytotoxicity consistently ob-
served with DC-stimulated CD8 T cells from TIL, popu-
lations of freshly isolated TIL showed no cytotoxicity
against autologous tumor targets (data not shown).
Intracellular cytokine expression by cervical cancer-
specific T cells
To determine the pattern of Type 1 and Type 2 cytokine
expression in the populations of CD8 T lymphocytes col-
lected from PBL and TIL, two-color flow cytometric anal-
ysis of intracellular IFN- or IL-4 expression by CD8 T
cells was performed before and after in vitro culture with
HPV16 or HPV18 E7-loaded autologous DC. As described
in Table 3, at the beginning of culture, significantly more
CD8 T cells from TIL expressed IFN- than PBL-derived
CD8 T cells following PMA and ionomycin activation (P
 0.05). In contrast, IL-4 expression was found at low, but
significantly higher levels in CD8 T cells from PBL (P 
0.05) when compared to TIL (Table 3). When pure popu-
lations of CD8 T cells were tested after stimulation with
E7-loaded DC and further in vitro expansion, significantly
higher numbers of CD8 T cells from TIL were found to
contain intracellular IFN- compared to CD8 T cells de-
rived from PBL (Table 3). IL-4 expression was again sig-
nificantly higher in CD8 T cells derived from PBL when
compared to IL-4 expression by CD8 T cells obtained
from TIL, with higher numbers of double positive (i.e.,
IFN-/IL-4) CD8 T cells from PBL (Table 3). Similar
results were consistently obtained in several repetitive anal-
yses for all patients. Unactivated (i.e., resting) CD8 T cells
failed to stain for IFN- or IL-4, and similarly, FITC-anti-
IgG2a and PE-anti-IgG1 isotype controls did not stain either
activated or unactivated CD8 T cells (data not shown).
Discussion
Despite the presence of a lymphocytic infiltrate consti-
tuted of Th1 cytokine expressing antigen-experienced
CD8 T cells [9,10,36], many human tumors, including
cervical cancers, grow relentlessly, suggesting that these
preferentially recruited lymphocyte populations may even-
tually become functionally suppressed in vivo [29–32]. The
mechanisms responsible for this tumor-induced suppression
are not completely understood but may include the release
of immunosuppressive cytokines, such as TGF-, IL-10
[reviewed in 29,30], or vascular endothelial growth factor
[37] by infiltrating mononuclear cells and tumor cells, or the
incompetent or defective antigen presentation by antigen
presenting cells that fail to offer adequate help for inducing
or maintaining effective immune responses [38].
Dendritic cells are the most potent antigen presenting
cells known in humans and play a crucial role during the
priming and reactivation of antigen-specific immune re-
sponses [19–21]. Because the E6 and E7 transforming on-
coproteins of the high-risk genotypes of human papilloma-
virus (i.e., HPV16 and HPV18) are constantly expressed in
the vast majority of cervical cancers, E6 and/or E7 could be
ideal candidates as potential tumor-specific targets for cer-
vical cancer immunotherapy [15–18]. However, cervical
cancer patients are often severely immunocompromised due
to multiple courses of chemotherapy and/or radiation ther-
apy during tumor progression [39–41]. Adoptive infusions
of tumor-specific in vitro-activated T cells, which avoid the
potential problems associated with inducing a CTL response
in vivo, might therefore be a more effective approach for
control of tumor growth in patients with cervical cancer
refractory to standard treatment modalities. Large numbers
of Type 1 cytokine-expressing and antigen-experienced
Table 2
Expression of TcR  chain in CD8 T cells derived from PBL and TIL of cervical cancer patients
Patient 1 Patient 2 Patient 3
Before After Before After Before After
% MFI % MFI % MFI % MFI % MFI % MFI
PBL 100 41 80 11 100 49 79 13 100 36 87 12
TIL 98 16 78 9 96 11 69 8 99 14 69 9
Percentage and mean fluorescence intensity (MFI) of TcR  chain-positive CD8 T cells before and after in vitro stimulation with E7-pulsed autologous
dendritic cells. The difference in TcR  chain expression in PBL versus TIL before DC stimulation was significant at P  0.05. No significance difference
in TcR  chain expression was noted in PBL versus TIL after DC stimulation.
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CD8 T cells are commonly detected in TIL relative to
PBL, suggesting that TIL may be a favorable source of
CD8 T cells for immunotherapy. However, the immuno-
competence of human TIL and the possibility of consis-
tently restoring their tumor-specific lytic activity in vitro
remains an unresolved issue.
In this study, as a basis for the development of more
effective immunotherapy protocols for the treatment of met-
astatic disease, we performed a careful functional analysis
of lymphocytes derived from PBL and TIL before and after
in vitro stimulation with tumor antigen-pulsed autologous
mature DC.
We found TIL to be a superior source of tumor-specific
CTL compared to PBL. Although TIL were not cytotoxic
immediately after collection, induction of higher cytotoxic
activity against autologous HPV16 or HPV18 tumor cells
was consistently noted in E7-loaded DC-stimulated CD8 T
cells from TIL when compared to CD8 T cells derived
from PBL. The lack of significant cytotoxicity against
HLA-identical autologous LCL confirmed that, although
these TIL-derived CTL were highly cytolytic against autol-
ogous tumor cells, they failed to kill autologous control
target cells expressing different antigens. Furthermore, the
fine specificity of the TIL-derived populations of CTL was
also confirmed by the significantly higher block in cytotoxic
activity detected using anti-HLA class I MAb when com-
pared to PBL-derived CTL and by their minor cytotoxic
activity against K562 natural killer-sensitive target cells. In
this regard, the lack of a complete block in cytotoxicity by
anti-HLA class I MAb can be at least partially explained by
the presence of a heterogenous population of CTL at the
time of the cytotoxicity assays. The possibility of HLA-
Fig. 2. Tumor-specific CD8 CTL responses induced in PBL (left) and TIL (right) by full-length HPV16/18 E7-loaded DC in three cervical cancer patients,
measured in a 6-h 51Cr-release assay. Percentage of lysis ( standard deviation) at a 20:1 effector:target cell ratio is shown. Anti-HLA class I blocking
antibody (W6/32) and isotype control MAb (data not shown) were used at 50 g/ml. Patients 1 (A), 2 (B), and 3 (C); 1, autologous tumor; 2, autologous
tumorW6/32 anti-class I MAb; 3, autologous LCL; 4, K562.
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unrestricted lysis of target cells by at least some tumor-
specific CD8 T cells cannot be excluded [42]. Indeed,
high-avidity/high-affinity tumor-specific CD8 CTL with
the ability to kill tumor target cells using either HLA class-
I-restricted or a HLA class-I-unrestricted mechanisms have
been previously reported [42].
Lymphocytes used at the time of in vitro stimulation with
HPV16 or HPV18 E7-loaded DC were predominantly
CD4 T cells in PBL and CD8 T cells in TIL (CD4:CD8
ratios, 2:1 and 0.8:1, respectively). After in vitro restimu-
lation with antigen-loaded fully mature DC, CD4 T cells
remained predominant in PBL cultures, while in TIL cul-
tures a predominant population of CD8 T cells was again
consistently noted. CD56/CD16/CD3 NK cells and
CD8/CD56 T cells were predominant in PBL compared
to TIL at the beginning of culture. However, after in vitro
stimulation and expansion of CD8 T cells, TIL contained
a significantly higher percentage of CD8/CD56 T cells
compared to PBL. In agreement with previous studies
[43,44], the percentage of CD8/CD56 T cells in the PBL
and TIL cultures was found to correlate with the overall
cytotoxic activity.
TIL derived from cervical cancer specimens have been
reported to have reduced expression of CD3, an impor-
tant signaling component of the T cell receptor [45].
Importanty, T cells with suppressed  chain have been
demonstrated to exhibit diminished proliferation and pro-
duction of cytokines [45]. In this study, consistent with
this previous report [45], we found a lower relative ex-
pression of TcR  chain in freshly isolated CD8 T cells
derived from TIL compared to PBL. However, no signif-
icant difference in TcR  chain expression compared to
PBL was detected after in vitro stimulation of TIL with
HPV16 and HPV18 E7-pulsed fully mature DC. These
data, therefore, demonstrate that fully mature DC stimu-
lation may provide culture conditions able to induce
restoration of TcR  chain expression in TIL to the level
detected in activated PBL populations.
Induction of in vivo antitumor immune responses and
effective adoptive cellular immunotherapy have been re-
ported to be more dependent on the induction of a host
immune response triggered by Type 1 cytokines (i.e.,
IL-2, IFN-, GM-CSF) than the in vitro cytotoxic activity
of the responder or transferred lymphocytes [46 – 48]. In
support of this view, studies of Tartour et al. [10] have
recently shown that poor prognosis and tumor recurrence
in cervical cancer patients was associated with detection
of low numbers of IFN- mRNA copies in fresh tumor
biopsy specimens. Furthermore, a significant dysfunction
of Type 1 T cell responses concomitant with an abnor-
mally elevated production of Type 2 cytokines in cervical
cancer patients has been reported [49], suggesting that
tumor progression may be associated with a preferential
and unprotective Type 2 T cell response. In our previous
work comparing the phenotypes of lymphocytes derived
from PBL and TIL in invasive cervical cancer patients
[36], IFN- expression was predominant in the CD8 T
cell populations derived from TIL. Consistent with these
data, in all three patients studied in this report, IFN-
expression was predominant in TIL compared to the
PBL-derived CD8 T cell populations IL-4 T cells were
detected in low numbers and mainly in PBL. After in
vitro stimulation with tumor antigen-pulsed DC, a greater
proportion of IFN- Th1 cells was again detected in
TIL compared to PBL. This pattern of cytokine expres-
sion in TIL, combined with the consistently inverted CD4
to CD8 ratios, further supports the concept of a specific
recruitment and accumulation of a high concentration of
antigen-experienced tumor-specific CD8 T lymphocytes
in the tumor tissue [36,50].
In conclusion, we showed that TIL may constitute a
superior source of tumor-specific HLA class-I-restricted
CTL compared to PBL. Although poor immune responses
by explanted T lymphocytes might be expected, it is possi-
ble to normalize defective TIL responses by in vitro T cell
stimulation with professional antigen presenting cells, such
as fully mature DC. These results, combined with the fact
that the most critical component of successful adoptive
immunotherapy of cancer is the identification and isolation
of large numbers of lymphocytes with potent and specific
antitumor activity, support further research efforts for the
development of improved protocols to counteract mecha-
nisms leading to impaired TIL function and thus exploit
these cells as potential lymphocyte populations for use in
adoptive cellular immunotherapy of cervical cancer pa-
tients.
Table 3
Percentages of IFN-- and IL-4-positive CD8 T cells from PBL and TIL derived from cervical cancer patients
Patient 1 Patient 2 Patient 3
Before After Before After Before After
IFN- IL-4 IFN- IL-4 IFN- IL-4 IFN- IL-4 IFN- IL-4 IFN- IL-4
PBL 12 3 48 11 20 4 49 12 14 3 61 19
TIL 63 0.5 78 4 59 1 89 3 56 0.5 65 7
Percentages of IFN-- and IL-4-positive CD8 T cells from PBL and TIL before and after in vitro stimulation with E7-pulsed autologous dendritic cells.
The difference in IFN- expression in PBL versus TIL before and after DC stimulation was significant at P  0.05. The difference in IL-4 expression in PBL
versus TIL before and after DC stimulation was significant at P  0.05.
278 A.D. Santin et al. / Gynecologic Oncology 89 (2003) 271–280
Acknowledgments
This work was supported in part by grants from the
Camillo Golgi Foundation, Brescia, Italy, and the Lega
Nazionale contro i Tumori Sezione di Brescia.
References
[1] DiSaia PJ, Creasman WT. Cervical cancer. In: DiSaia PJ, Creasman
WT, editors. Clinical gynecologic oncology. St. Louis: Mosby–Year
Book, Inc., 1997. p. 1–106.
[2] Brinton LA. Epidemiology of cervical cancer: Overview. In: Munoz
N, Bosh F, Shah KV, Meheus A, editors. The epidemiology of human
papillomavirus and cervical cancer, Vol. 119. Lyon, France: IARC
Science Publications, 1992. p. 3–23.
[3] Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J,
Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of
human papillomavirus in cervical cancer: a worldwide perspective.
J Natl Cancer Inst 1995;87:796–802.
[4] Penn I. Cancers of the anogenital region in renal transplant recipients:
analysis of 65 cases. Cancer 1988;53:539–45.
[5] Rellihan MA, Dooley DP, Burke TW, Berkland ME, Longfield RN.
Rapidly progressing cervical cancer in a patient with human immu-
nodeficiency virus infection. Gynecol Oncol 1990;36:435–8.
[6] Nasiell K, Roger V, Nasiell M. Behaviour of mild cervical dysplasia
during long term follow-up. Obstet Gynecol 1986;67:665–9.
[7] Rogozinski T, Jablonska S, Jarzabek-Chorzelska M. Role of cell-
mediated immunity in spontaneous regression of plane warts. Int J
Dermatol 1988;27:322–8.
[8] Morison WL. Viral warts, herpes simplex, and herpes zoster in
patients with secondary immune deficienses and neoplasms. Br J
Dermatol 1975;92:625–33.
[9] Chao HT, Wang PH, Tseng JY, Lai CR, Chiang SC, Yuan CC.
Lymphocyte-infiltrated FIGO stage IIB squamous cell carcinoma of
the cervix is a prominent factor for disease-free survival. Eur J
Gynaec Oncol XX 1998;2:136–40.
[10] Tartour E, Gey A, Sastre-Garau E, Lombard Surin I, Mosseri V,
Fridman WH. Prognostic value of intratumoral interferon gamma
messanger RNA expression in invasive cervical carcinomas. J Natl
Cancer Inst 1998;90:287–94.
[11] Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrel CJ.
Increased age and mortality associated with cervical carcinomas neg-
ative for human papillomavirus RNA. Lancet 1991;338:910–13.
[12] Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against
human papilloma virus type 16 tumor cells with recombinant vaccinia
viruses expressing E6 and E7. Virology 1991;181:62–9.
[13] Chen L, Thomas EK, Hu S-L, Hellstrom I, Hellstrom KE. Human
papilloma virus type 16 nucleoprotein E7 is a tumor rejection antigen.
Proc Natl Acad Sci USA 1991;88:110–14.
[14] Chen L, Mizuno MT, Singal MC, Hu S-L, Galloway DA, Hellstrom
I, Hellstrom KE. Induction of cytotoxic T lymphocytes specific for a
syngeneic tumor expressing the E6 oncoprotein of human papilloma
virus type 16. J Immunol 1992;148:2617–21.
[15] Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg
SA, Steller MA. Generation of tumor-specific cytolytic T lympho-
cytes from peripheral blood of cervical cancer patients by in vitro
stimulation with a synthetic human papillomavirus type 16 E7
epitope. Am J Obstet Gynecol 1996;175:1586–93.
[16] Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervi-
cal cancer tissue with human papillomavirus-specific cytotoxic T-
lymphocytes. Cancer Res 1997;57:2943–50.
[17] Nimaco M, Fiander AN, Wilkinson GWG, Borysiewicz LK, Man S.
Human papillomavirus-specific cytotoxic T lymphocytes in patients
with cervical intraepithelial neoplasia grade III. Cancer Res 1997;57:
4855–61.
[18] Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW,
Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME,
Rutherford E, Hickling JK, Inglis SC. A recombinant vaccinia virus
encoding human papillomavirus types 16 and 18, E6 and E7 proteins
as immunotherapy for cervical cancer. Lancet 1996;347:1523–7.
[19] Steinman RM. The dendritic cell system and its role in immunoge-
nicity. Annu Rev Immunol 1996;9:271–96.
[20] Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher
B, Konwalinka GO, Fritsch P, Steinman RM, Shuler G. Proliferating
dendritic cell progenitors in human blood. J Exp Med 1994;180:83–
93.
[21] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen
by cultured human dendritic cells is maintained by granulocyte/
macrophage colony stimulating factor plus interleukin-4 and down-
regulated by tumor necrosis factor . J Exp Med 1994;179:1109–16.
[22] Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B,
Engleman EG, Levy R. Vaccination of patients with B-cell lym-
phoma using autologous antige-pulsed dendritic cells. Nature Med
1996;2:52–8.
Fig. 3. Representative dot plot analysis of intracellular IFN- versus IL-4
expression by CD8 T cells from an individual patient after in vitro culture
with full-length HPV16/18 E7-loaded DC. Lymphocytes were activated by
PMA and ionomycin as described under Materials and Methods. Numbers
in the quadrants represent the percentages of cytokine-positive CD8 T
lymphocytes.
279A.D. Santin et al. / Gynecologic Oncology 89 (2003) 271–280
[23] Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg
G, Schadendorf D. Vaccination of melanoma patients with peptide- or
tumor lysate-pulsed dendritic cells. Nature Med 1998;4:328–32.
[24] Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P,
Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P,
Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G. Vacci-
nation with Mage-3A1 peptide-pulsed mature, monocyte-derived
dendritic cells expands specific cytotoxic T cells and induces regres-
sion of some metastases in advanced stage IV melanoma. J Exp Med
1999;190:1669–78.
[25] Kugler A, Stuhler G, Walden P, Zoller G, Zobiwalski A, Brossart P,
Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B,
Kanz L, Muller GA, Ringert R-H. Regression of human metastatic
renal cell carcinoma after vaccination with tumor cell-dendritic cells
hybrid. Nature Med 2000;6:332–6.
[26] Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA,
Levine JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric
solid tumor patients with tumor lysate-pulsed dendritic cells can
expand specific T cells and mediate tumor regression. Cancer Res
2001;61:8513–19.
[27] Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adop-
tive immunotherapy of cancer with tumor-infiltrating lymphocytes.
Science 1987;233:1318–22.
[28] Spiess P, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor
infiltrating lymphocytes expanded in recombinant interleukin-2.
J Natl Cancer Inst 1987;79:1067–73.
[29] Ioannides CG, Whiteside TL. T cell recognition of human tumors:
implications for molecular immunotherapy of cancer. Clin Immunol
Immunopathol 1993;66:91–106.
[30] Whiteside TL. Tumor infiltrating lymphocytes in human malignan-
cies. Austin TX: Medical Intelligence Unit, R.G. Landes; 1993.
[31] Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I,
Dubois D’Enghien C, Lee R, Debre B, Fridman WH. Variable ex-
pression of CD3- chain in tumor infiltrating lymphocytes (TIL)
derived from renal-cell carcinoma: relationship with TIL phenotype
and function. Int J Cancer 1995;63:205–12.
[32] Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier J-P,
Pfreundschuh A. T cells from patients with Hodgkin’s disease have a
defective T-cell receptor  chain expression that is reversible by
T-cell stimulation with CD3 and CD28. Blood 1996;88:236–41.
[33] Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Cannon
M, Hiserodt JC, Pecorelli S, Parham GP. Expression of surface
antigens during the differentiation of human dendritic cell versus
macrophages from blood monocytes in vitro. Immunobiology 1999;
200:187–204.
[34] Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan DJ,
Pecorelli S, Parham GP, Cannon M. Induction and characterization of
human papillomavirus-specific cytotoxic T lymphocytes by E7 pulsed
autologous dendritic cells in patients with HPV-16 and 18 positive
cervical cancer. J Virol 1999;3:5402–10.
[35] Whiteside TL, Miescher S, MacDonald HR, Von Fliedner V. Sepa-
ration of tumor infiltrating lymphocytes from tumor cells in human
solid tumors. A comparison between velocity sedimentation and dis-
continuous density gradient. J Immunol Methods 1986;90:221–33.
[36] Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham
GP, Hermonat P. Tumor infiltrating lymphocytes contain higher num-
bers of type 1 cytokine expressors and DR T cells compared with
lymphocytes from tumor draining lymph nodes and peripheral blood
in patients with cancer of the uterine cervix. Gynecol Oncol 2001;
81:424–32.
[37] Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S,
Parham GP. Secretion of vascular endothelial growth factor in ade-
nocarcinoma and squamous cell carcinoma of uterine cervix. Obstet
Gynecol 1999;94:78–82.
[38] Melichar B, Savary C, Kudelka AA, Verscharaegen C, Kavanagh JJ,
Edwards CL, Platsoucas CD, Freedman RL. Lineage-negative human
leukocyte antigen-DR cells with the phenotype of undifferentiated
dendritic cells in patients with carcinoma of the abdomen and pelvis.
Clin Cancer Res 1998;4:799–809.
[39] Onsurd M, Thorsby E. Long term changes in natural killer cytotox-
icity after external pelvic radiotherapy. Int J Radiat Oncol Biol Phys
1981;7:609–14.
[40] Balaram P, Pillai R, Padmanabhan TK, Abraham T, Hareendran NK,
Nair MK. Immune function in malignant cervical neoplasia: A mul-
tiparameter analysis. Gynecol Oncol 1988;31:409–23.
[41] Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli
S, Cannon M, Parham GP. Effects of concurrent cisplatinum admin-
istration during radiotherapy versus radiotherapy alone on the im-
mune function of patients with cancer of the uterine cervix. Int J
Radiat Oncol Biol Phys 2000;48:997–1006.
[42] Roberts TE, Shipton U, Moore M. Role of MHC class I antigens and
the CD3 complex in the lysis of autologous human tumors by T cell
clones. Int J Cancer 1987;39:436–41.
[43] Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jaya-
prabhu S, Pecorelli S, Parham GP, Cannon M. Expression of CD56
by human papilomavirus E7-specific CD8 cytotoxic T lymphpcytes
correlates with increased intracellular perforin expression and en-
hanced cytotoxicity against HLA A2-matched cervical tumor cells.
Clin Cancer Res 2001;7:804s–10s.
[44] Hilders CGJM, Ras L, Van Eendenburg JDH, Nooyen Y, Fleuren GJ.
Isolation and characterization of tumor-infiltrating lymphocytes from
cervical carcinoma. Int J Cancer 1994;57:805–13.
[45] Kono K, Ressing ME, Brandt RMP, Melief JM, Potkul RK, Anders-
son B, Petersson M, Kast WM, Kiessling R. Decreased expression of
signal-transducing  chain in peripheral T cells and natural killer cells
in patients with cervical cancer. Clin Cancer Res 1996;2:1825–8.
[46] Romagnani S. Human TH1 and TH2 subsets: regulation of differen-
tiation and role in protection and immunopathology. Int Arch Allergy
Immunol 1992;98:279–85.
[47] Barth RJJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and
tumor necrosis factor have a role in tumor regression mediated by
murine CD8 tumor infiltrating lymphocytes. J Exp Med 1991;173:
647–54.
[48] Goedegebuure PS, Zuber M, Leonard-Vidal DL, Burger UL, Cusack
JC, Chang MP, Douville LM, Eberlein TJ. Reactivation of murine
tumor-infiltrating lymphocytes with solid phase anti-CD3 antibody:
in vitro cytokine production is associated with in vivo efficacy. Surg
Oncol 1994;3:79–89.
[49] Clerici M, Shearer GM, Clerici E. Cytokine disregulation in invasive
cervical carcinoma and other human neoplasias: time to consider the
Th1/Th2 paradigm. J Natl Cancer Inst 1998;90:261–2.
[50] Yamamoto K, Masuko K, Takahashi S, Ikeda Y, Kato T, Mizushima
Y, Hayashi K, Nishioka K. Accumulation of distinct T cell clonotypes
in human solid tumors. J Immunol 1995;154:1804–9.
280 A.D. Santin et al. / Gynecologic Oncology 89 (2003) 271–280
